Tristetraprolin, a Potential Safeguard Against Carcinoma: Role in the Tumor Microenvironment

Diwen Zhang; Zhigang Zhou; Ruixia Yang; Sujun Zhang; Bin Zhang; Yanxuan Tan; Lingyao Chen; Tao Li; Jian Tu

doi:10.3389/fonc.2021.632189

Tristetraprolin, a Potential Safeguard Against Carcinoma: Role in the Tumor Microenvironment

Front Oncol. 2021 May 7:11:632189. doi: 10.3389/fonc.2021.632189. eCollection 2021.

Authors

Diwen Zhang^{1

2}, Zhigang Zhou³, Ruixia Yang¹, Sujun Zhang⁴, Bin Zhang¹, Yanxuan Tan¹, Lingyao Chen⁵, Tao Li⁶, Jian Tu^{1

5}

Affiliations

¹ Institute of Pharmacy and Pharmacology, University of South China, Hengyang, China.
² Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
³ The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
⁴ Department of Experimental Animals, University of South China, Hengyang, China.
⁵ Pharmacy School of Guilin Medical University, Guilin, China.
⁶ Shanghai Veterinary Research Institute, Chinese Academy of Agriculture Science, Shanghai, China.

Abstract

Tristetraprolin (TTP), a well-known RNA-binding protein, primarily affects the expression of inflammation-related proteins by binding to the targeted AU-rich element in the 3' untranslated region after transcription and subsequently mediates messenger RNA decay. Recent studies have focused on the role of TTP in tumors and their related microenvironments, most of which have referred to TTP as a potential tumor suppressor involved in regulating cell proliferation, apoptosis, and metastasis of various cancers, as well as tumor immunity, inflammation, and metabolism of the microenvironment. Elevated TTP expression levels could aid the diagnosis and treatment of different cancers, improving the prognosis of patients. The aim of this review is to describe the role of TTP as a potential safeguard against carcinoma.

Keywords: RNA binding protein; carcinoma; potential safeguard; tristetraprolin (TTP); tumor microenvironment (TME).

Publication types

Review